Ligands to the integrin receptor α(v)β3

Expert Opinion on Therapeutic Patents

Volumn 10, Issue 9, 2000, Pages 1367-1383

  Duggan, M E ^a   Hutchinson, J H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Angiogenesis; Integrin; Osteoporosis; Vitronectin; (v)b3

Indexed keywords

AMINOBENZOIC ACID DERIVATIVE; AMINOPYRIDINE DERIVATIVE; ANTICOAGULANT AGENT; ARGININE; ASPARTIC ACID; BENZIMIDAZOLE; CYCLOPEPTIDE; ECHISTATIN; EMD 66203; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCINE; GUANIDINE DERIVATIVE; IMIDAZOLE; INTEGRIN; INTEGRIN RECEPTOR; LIGAND; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY LM 609; NEW DRUG; PHENYLALANINE DERIVATIVE; PROPIONIC ACID DERIVATIVE; PYRIDINE; PYRIDINE DERIVATIVE; PYRIMIDINE; QUINAZOLINE DERIVATIVE; SC 68448; SULFONAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITRONECTIN RECEPTOR;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BETA CHAIN; CANCER; CELL INTERACTION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG POTENCY; DRUG STRUCTURE; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; LIGAND BINDING; MOUSE; NONHUMAN; OSTEOPOROSIS; PATENT; PROTEIN BINDING; RAT; RECEPTOR AFFINITY; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0033863801     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.10.9.1367     Document Type: Review

References (54)

1. Intergins and other cell adhesion molecules
2. Integrins: Versatility, modulation and signaling in cell adhesion
3. Targets in integrin research
4. Crystal structure of the a domain from the α subunit of integrin CR3 (CD11b/CD18)
5. RGD and other recognition sequences for integrins
6. Integrin affinity modulation
7. Demonstration of mechanical connections between integrins, cytoskeletal filaments, and nucleoplasm that stablize nuclear structure
8. Comparison of cDNA-derived protein sequences of the human fibronectin and vitronectin receptor α-subunits and platelet glycoprotein IIb
9. Purification of glycoproteins IIb and III from human platelet plasma membranes and characterization of a calcium-dependent glycoprotein IIb-III complex
10. Expression of recombinant platelet glycoprotein IIbIIIa results in a functional fibrinogen-binding complex
11. Efficient surface expression of platelet GP IIb-IIIa requires both subunits
12. Integrin signaling: The platelet paradigm
13. Platelet activation in unstable coronary disease
14. Platelet glycoprotein IIb/IIIa antagonists
15. GPIIb/IIIa antagonists
16. Non-peptide fibrinogen receptor antagonist. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist
17. Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. a proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and GP IIb-IIIa receptor
18. Cloning, primary structure and properties of a novel human integrin beta subunit
19. Normal development, wound healing, and adenovirus susceptibility in β5-deficient mice
20. Vitronectin and its receptors
21. αvβ3 integrin antagonists as inhibitors of bone resorption
22. Integrin (αvβ3)-ligand interaction
23. Treatment of postmenopausal osteoporosis
24. Guidelines for diagnosis and management of osteoporosis
25. Osteonal and hemi-osteonal remodeling: The spatial and temporal framework for signal traffic in adult human bone
26. Biochemical characterization of human osteoclast integrins. osteoclasts express αvβ3, α2β1 and αvβ1 integrins
27. Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit cell spreading and dentine resorption by osteoclasts
28. Monoclonal antibodies against osteoclasts inhibit bone resorption in vitro
29. The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats
30. Echistatin is a potent inhibitor of bone resorption in culture
31. 7 high affinity echistatin binding sites (RGD-integrtins)
32. A peptidomimetic antagonist of the αvβ3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo
33. An orally active αvβ3 antagonist prevents bone loss in the ovariectomized rat model
34. The role of α(v) integrins during angiogenesis: Insights into potential mechanisms of action and clinical development
35. 3 for angiogenesis
36. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
37. 3 blocks human breast cancer growth and angiogenesis in human skin
38. 3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy
39. Definition of two angiogenic pathways by distinct α(v) integrins
40. 3 inhibit retinal neovascularization in a murine model
41. 3 antagonist
42. 3 integrin for a new cancer therapy
43. 3 selectivity requirements
44. 3
45. Orally bioavailable nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimetics
46. Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model
47. Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis
48. Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist
49. Dissociation Constants of Organic Bases
50. 3 antagonist L-767,635
51. 1 moiety
52. Alendronate and osteoporosis
53. The effects of raloxifene on tibia histomorphometry in ovariectomized rats
54. 3 integrins are osteoclerotic because of dysfunctional osteoclasts